HOME > 業績

業績

(*Corresponding author)（○：当研究室が主となって行った研究成果)

2020

  1. Ishigaki K, Akiyama M, Kanai M, Takahashi A, Kawakami E, Sugishita H, Sakaue S, Matoba N, Low SK, Okada Y, Terao C, Amariuta T, Gazal S, Kochi Y, Horikoshi M, Suzuki K, Ito K, Koyama S, Ozaki K, Niida S, Sakata Y, Sakata Y, Kohno T, Shiraishi K, Momozawa Y, Hirata M, Matsuda K, Ikeda M, Iwata N, Ikegawa S, Kou I, Tanaka T, Nakagawa H, Suzuki A, Hirota T, Tamari M, Chayama K, Miki D, Mori M, Nagayama S, Daigo Y, Miki Y, Katagiri T, Ogawa O, Obara W, Ito H, Yoshida T, Imoto I, Takahashi T, Tanikawa C, Suzuki T, Sinozaki N, Minami S, Yamaguchi H, Asai S, Takahashi Y, Yamaji K, Takahashi K, Fujioka T, Takata R, Yanai H, Masumoto A, Koretsune Y, Kutsumi H, Higashiyama M, Murayama S, Minegishi N, Suzuki K, Tanno K, Shimizu A, Yamaji T, Iwasaki M, Sawada N, Uemura H, Tanaka K, Naito M, Sasaki M, Wakai K, Tsugane S, Yamamoto M, Yamamoto K, Murakami Y, Nakamura Y, Raychaudhuri S, Inazawa J, Yamauchi T, Kadowaki T, Kubo M, Kamatani Y. Nat Genet. 2020 Jul;52(7):669-679.
  2. Fujimoto Y, Inoue, N, Morimoto K, Watanabe T, Hirota S, Imamura M, Matsushita Y, Katagiri T, Okamura H, *Miyoshi Y. Significant association between high serum CCL5 levels and better disease-free survival of patients with early breast cancer. Cancer Sci. 2020 Jan;111(1):209-218.
  3. ○ #Kimura R, #Yoshimaru T, #Matsushita Y, Matsuo T, Ono M, Park JH, Sasa M, Miyoshi Y, Nakamura Y, *Katagiri T. The GALNT6-LGALS3BP axis promotes breast cancer cell growth. Int J Oncol. 2020 Feb;56(2):581-595. (# equal contribution)

2019

  1. Ohigashi I, Tanaka Y, Kondo K, Fujimori S, Kondo H, Palin AC, Kozai M, Matsushita Y, Uda S, Kubota H, Murata S, Tanaka K, Katagiri T, Kosako H, *Takahama Y. Trans-omics impact of thymoproteasome in cortical thymic epithelial cells. Cell Rep. 2019 Nov 26;29(9):2901-2916.
  2. ○*Low SK, Ito H, Matsuo K, Tanikawa C, Matsuda K, Saito H, Sakurai-Yageta M, Nakaya N, Shimizu A, Nishizuka SS, Yamaji T, Sawada N, Iwasaki M, Tsugane S, Takezaki T, Suzuki S, Naito M, Waka K, Kamatani Y, Momozawa Y, Murakami Y, Inazawa J, Nakamura Y, Kubo M, Katagiri T, * Miki Y. Identification of the two novel breast cancer loci through large-scale genome-wide association study in the Japanese population. Sci Rep. 2019 Nov 22;9(1):17332.
  3. Inoue N, Li W, Fujimoto Y, Matsushita Y, Katagiri T, Okamura H, *Miyoshi Y. High Serum Levels of Interleukin-18 Are Associated With Worse Outcomes in Patients With Breast Cancer. Anticancer Res. 2019 Sep;39(9):5009-5018. (IF: 1.935)
  4. Chigira T, Nagatoishi S, Takeda H, Yoshimaru T, Katagiri T, *Tsumoto K. Biophysical characterization of the breast cancer-related BIG3-PHB2 interaction: Effect of non-conserved loop region of BIG3 on the structure and the interaction. Biochem Biophys Res Commun. 2019 Oct 8;518(1):183-189. (IF: 2.705)

2018

  1. *Momozawa Y, Iwasaki Y, Parsons MT, Kamatani Y, Takahashi A, Tamura C, Katagiri T, Yoshida T, Nakamura S, Sugano K, Miki Y, Hirata M, Matsuda K, Spurdle AB, *Kubo M. Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. Nat Commun. 2018 Oct 4;9(1):4083.
  2. Deng B, Tarhan YE, Ueda K, Ren L, Katagiri T, Park JH, *Nakamura Y. Critical role of estrogen receptor alpha O-glycosylation by N-acetylgalactosaminyltransferase 6 (GALNT6) in its nuclear localization in breast cancer cells. Neoplasia. 2018 Oct;20(10):1038-1044.
  3. Giraudet AL, Cassier PA, Iwao-Fukukawa C, Garin G, Badel JN, Kryza D, Chabaud S, Gilles-Afchain L, Clapisson G, Desuzinges C, Sarrut D, Halty A, Italiano A, Mori M, Tsunoda T, Katagiri T, Nakamura Y, Alberti L, Cropet C, Baconnier S, Berge-Montamat S, Pérol D, Blay JY. A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer. 2018 Jun 8;18(1):646.
  4. Kato Y, Zembutsu H, Takata R, Matsuura T, Kato R, Kanehira M, Iwasaki K, Yamada N, Katagiri T, Sugai T, Fujioka T, Nakamura Y, *Obara W. A prospective study to examine the accuracies and efficacies of prediction systems for response to neoadjuvant chemotherapy for muscle invasive bladder. Oncology Letters. 2018, Nov;16(5):5775-5784.
  5. Li HK, Sugyo A, Tsuji AB, Morokoshi Y, Minegishi K, Nagasu K, Kanda H, Harada Y, Nagayama S, Katagiri T, Nakamura Y, Higashi T, Hasegawa S. alpha-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibpdy against fizzled homolog 10. Cancer Sci. 2018 Jul;109(7):2302-2309.
  6. 〇 Daizumoto K, Yoshimaru T, Matsushita Y, Fukawa T, Uehara H, Ono M, Komatsu M, Kanayama H, *Katagiri T. A DDX31/mutant-p53/EGFR axis promotes multistep progression of muscle invasive bladder cancer. Cancer Res., 2018 May 1;78(9):2233-2247.
  7. ○ Miyagawa Y#, Matsushita Y#, Suzuki H, Komatsu M, Yoshimaru T, Kimura R, Yanai A, Honda J, Tangoku A, Sasa M, Miyoshi Y, *Katagiri T. Frequent downregulation of LRRC26 by epigenetic alterations is involved in the malignant progression of triple-negative breast cancers. Int J Oncol. 2018 Mar 5. (# contributed equally)
  8. Sato S, Nakamura T, Katagiri T, Tsuchikawa T, Kushibiki T, Hontani K, Takahashi M, Inoko K, Takano H, Abe H, Takeuchi S, Ono M, Kuwabara S, Umemoto K, Suzuki T, Sato O, Nakamura Y, Hirano S. Molecular targeting of cell-permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferation. Oncotarget. 2017 Oct 19;8(69):113662-113672.
  9. Obara W, Kanehira M, Katagiri T, Kato R, Kato Y, Takata R. Present status and future perspective of peptide-based vaccine therapy for urological cancer. Cancer Sci. 2018, Mar; 109(3):550-559.

2017

  1. Nishimukai A, Inoue N, Kira A, Takeda M, Morimoto K, Araki K, Kitajima K, Watanabe T, Hirota S, Katagiri T, Nakamori S, Akazawa K, Miyoshi Y*. Tumor size and proliferative marker geminin rather than Ki67 expression levels significantly associated with maximum uptake of 18F-deoxyglucose levels on positron emission tomography for breast cancers. PLoS One. 2017 Sep 8;12(9):e0184508.
  2. Shigemizu D, Iwase T, Yoshimoto M, Suzuki Y, Miya F, Boroevich KA, Katagiri T, Zembutsu H*, Tsunoda T*. The prediction models for postoperative overall survival and disease-free survival in patients with breast cancer. Cancer Med. 2017 Jul;6(7):1627-1638
  3. 〇Yoshimaru T, Ono M, Bando Y, Chen YA, Mizuguchi K, Shima H, Komatsu M, Imoto I, Izumi K, Honda J, Miyoshi Y, Sasa M, Katagiri T*. A-kinase anchoring protein BIG3 coordinates oestrogen signaling in breast cancer cells. Nat Commun. 2017 May 30;8:15427. 【報道発表】乳がん細胞における新規エストロゲンシグナル制御機構の解明 〜新しいがん抑制因子の不活化機構の発見〜
  4. 〇Yoshimaru T*, Aihara K, Komatsu M, Matsushita Y, Okazaki Y, Toyokuni S, Honda J, Sasa M, Miyoshi Y, Otaka A, Katagiri T*. Stapled BIG3 helical peptide ERAP extends potent antitumor activity for breast cancer therapeutics. Sci Rep. 2017 May 12;7(1):1821 「報道発表」分子内架橋型ペプチドによるホルモン依存性乳がんの新規治療法の開発 〜臨床応用を見据えたペプチドの改良〜
  5. Iwamoto T*, Katagiri T, Niikura N, Miyoshi Y, Kochi M, Nogami T, Shien T, Motoki T, Taira N, Omori M, Tokuda Y, Fujiwara T, Doihara H, Gyorffy B, Matsuoka J. Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers. Oncotarget. 2017 Apr 18;8(16):26122-26128.
  6. Shikata Y, Yoshimaru T, Komatsu M, Katoh H, Sato R, Kanagaki S, Okazaki Y, Toyokuni S, Tashiro E, Ishikawa S, Katagiri T, Imoto M*. Protein kinase A inhibition facilitates the antitumor activity of xanthohumol, a valosin-containing protein inhibitor. Cancer Sci. 2017 Apr;108(4):785-794.
  7. ○Uno Y*, Takata R, Kito G, Yamazaki Y, Nakagawa K , Nakamura Y, Kamataki T, Katagiri T*. Sex- and age-dependent gene expression in human liver: an implication for drug-metabolizing enzymes. Drug Metabolism and Pharmacokinetics. 2017 Feb;32(1):100-107.
  8. Obara W*, Karashima T, Takeda K, Kato R, Kato Y, Kanehira M, Takata R, Inoue K, Katagiri T, Shuin T, Nakamura Y, Fujioka T. Effective induction of cytotoxic T cells recognizing an epitope peptide derived from Hypoxia-Inducible Protein 2 (HIG2) in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2017 Jan;66(1):17-24..

2016

  1. ○Nakamura T, Katagiri T, Sato S, Kushibiki T, Tsuchikawa T, Hirano S, Nakamura Y. Overexpression of C16orf74 is involved in aggressive pancreatic cancers. Oncotarget. 2016 Jul 28. doi: 10.18632/oncotarget.10912.
  2. Park JH, Jang M, Tarhan YM, Katagiri T, Sasa M, Miyoshi Y, Kalari KR, Suman VJ, Weinshilboum R, Wang L, Boughey JC, Goetz MP, Nakamura Y. Clonal expansion of anti-tumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. Int J Oncol. 2016 Aug;49(2):471-8.

2015

  1. Imamura M, Nishimukai A, Higuchi T, Ozawa H, Yanai A, Miyagawa Y, Murase K, Sakita I, Hatada T, Takatsuka Y, Katagiri T, Miyoshi Y. High levels at baseline of serum pyridinoline crosslinked carboxyterminal telopeptide of type I collagen are associated with worse prognosis for breast cancer patients. Breast Cancer Res Treat. 2015 Dec;154(3):521-31.
  2. ○Kim NH,Yoshimaru T, Chen Y, Matsuo T, Komatsu M, Miyoshi Y, Tanaka E, Sasa M, Mizuguchi K, Katagiri T*. BIG3 inhibits the estrogen-dependent nuclear translocation of PHB2 via multiple Karyopherin-alpha proteins in breast cancer cells. PLoS One. 2015 Jun 8;10(6):e0127707.
  3. ○Yoshimaru T,Komatsu M, Miyoshi, Honda J, Sasa M, Katagiri T*. Therapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer. Cancer Sci. 2015 May;106(5):550-8.
  4. ○Yanai A, Inoue N, Yagi T, Nishimukai A, Miyagawa Y, Murase K, Imamura M, Enomoto Y, Takatsuka Y, Watanabe T, Hirota S, Sasa M, Katagiri T, Miyoshi Y. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER+, and HER2- Breast Cancer. Clin Breast Cancer. 2015 Jun;15(3):197-203.
  5. Lo PH, Tanikawa C, Katagiri T, Nakamura Y, Matsuda K. Identification of novel epigenetically inactivated gene, PAMR1 in breast carcinoma. Oncol Rep. 2015 Jan;33(1):267-73.

2014

  1. ○Yoshimaru T, Komatsu M, Tashiro E, Imoto M, Osada H, Miyoshi Y, Honda J, Sasa M, Katagiri T*. Xanthohumol suppresses oestrogen-signalling in breast cancer through the specific inhibition of BIG3-PHB2 interactions. Sci Rep. 2014. Dec 8;4:7355.
  2. ○Matsuo T, Dat LT, Komatsu M, Yoshimaru T, Daizumoto K, Sone S, Nishioka Y, Katagiri T*. Early growth response 4 is involved in cell proliferation of small cell lung cancer through transcriptional activation of its downstream genes. PLoS One. 2014 Nov 20;9(11):e113606. PubMed
  3. ○Chen YA, Murakami Y, Ahmad S, Yoshimaru T, Katagri T, Mizuguchi K. Brefeldin a-inhibited guanine nucleotide-exchange protein 3 (BIG3) is predicted to interact with its partner through an ARM-type alpha-helical structure. BMC Res Notes. 2014 Jul 6;7(1):435.
  4. Yoshimura S, Tsunoda T, Osawa R, Harada M, Watanabe T, Hikichi T, Katsuda M, Miyazawa M, Tani M, Iwahashi M, Takeda K, Katagiri T, Nakamura Y, Yamaue H. Identification of an HLA-A2-restricted epitope peptide derived from hypoxia-inducible protein 2 (HIG2). PLoS One 2014 Jan 8;9(1):e85267.
  5. ○Matsuo T, Komatsu M, Yoshimaru T, Kiyotani K, Miyoshi Y, Sasa M, Katagiri T*. Involvement of B3GALNT2 overexpression in cell growth of breast cancer. Int J Oncol. 2014 Feb;44(2):427-34.

2013

  1. ○Low SK, Takahashi A, Ashikawa K, Inazawa J, Miki Y, Kubo M, Nakamura Y, Katagiri T. Genome-wide association study of breast cancer in the Japanese population. PLoS One. 2013 Oct 15;8(10):e76463.
  2. ○Yoshimaru T,Komatsu M, Matsuo T, Chen YA, Murakami,Y Mizuguchi K, Mizohata E, Inoue T, Akiyama M, Yamaguchi R, Imoto S, Miyano S, Miyoshi Y, Sasa M, Nakamura Y, Katagiri T*. Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells. Nat. Communi. 2013;4:e2443.
  3. Yanai A, Miyagawa Y, Murase K, Imamura M, Yagi T, Ichii S, Takatsuka Y, Ito T, Hirota S, Sasa M, Katagiri T, Miyoshi Y. Influence of body mass index on clinicopathological factors including estrogen receptor, progesterone receptor, and Ki67 expression levels in breast cancers. Int J Clin Oncol. 2013 Jul 3.
  4. Kajita Y, Kato T Jr, Tamaki S, Furu M, Takahashi R, Nagayama S, Aoyama T, Nishiyama H, Nakamura E, Katagiri T, Nakamura Y, Ogawa O, Toguchida J. The transcription factor Sp3 regulates the expression of a metastasis-related marker of sarcoma, actin filament-associated protein 1-like 1 (AFAP1L1). PLoS One. 2013;8(1): e49709
  5. ○Komatsu M, Yoshimaru T, Matsuo T, Kiyotani, K, Miyoshi Y, Tanahashi T, Rokutan K, Yamaguchi R, Saito A, Miyano S, Nakamura Y, Sasa M, Shimada M, Katagiri T*. Molecular features of triple negative breast cancers by genome-wide gene expression profiling analysis. Int J Oncol. 2013 Feb;42(2):478-506

2012

  1. ○Fukawa T, Ono M, Matsuo T, Uehara H, Miki T, Nakamura Y, Kanayama H, Katagiri T*. DDX31 regulates the p53-HDM2 pathway and rRNA gene transcription through its interaction with NPM1 in renal cell carcinomas. Cancer Res. 2012 Nov 15;72(22):5867-77 [PubMed]
  2. Obara W, Ohsawa R, Kanehira M, Takata R, Tsunoda T, Yoshida K, Takeda K, Katagiri T, Nakamura Y, Fujioka T. Cancer Peptide Vaccine Therapy Developed from Oncoantigens Identified through Genome-wide Expression Profile Analysis for Bladder Cancer. Jpn J Clin Oncol. 2012 Jul;42(7):591-600.
  3. Murase K, Yanai A, Saito M, Imamura M, Miyagawa Y, Takatsuka Y, Inoue N, Ito T, Hirota S, Sasa M, Katagiri T, Fujimoto Y, Hatada T, Ichii S, Nishizaki T, Tomita N, Miyoshi Y. Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancers. Breast Cancer. 2012 Feb 23 (Epub) 2014.Jan21(1):52-7.
  4. Yoshioka H, Yamamoto S, Hanaoka H, Iida Y, Pramila P, Bishnuhari P, Higuchi T, Tominaga H, Oriuchi N, Nakagawa H, Shiba Y, Yoshida K, Osawa R, Katagiri T, Tsunoda T, Nakamura Y, Endo K. In vivo therapeutic effect of CDH3/P-Cadherin-targeting radioimmunotherapy. Cancer Immunol. Immunother. 2012; 61:1211-20.
  5. ○Dat LT, Matsuo T, Yoshimaru T, Kakiuchi S, Goto H, Hanibuchi M, Kuramoto T, Nishioka Y, Sone S, Katagiri T*. Identification of genes potentially involved in bone-metastasis by genome-wide gene-expression profiling analysis of non-small cell lung cancer in mice. Int J Oncol. 2012; 40:1455-69.[PubMed]

2011

  1. Kawai T, Caaveiro JM, Abe R, Katagiri T, Tsumoto K. Catalytic activity of MsbA reconstituted in nanodisc particles is modulated by remote interactions with the bilayer. FEBS Lett. 2011;585:3533-7. [PubMed]
  2. Furu M, Kajita Y, Nagayama S, Ishibe T, Shima Y, Uejima D, Aoyama T, Nakayama T, Nakamura T, Nakashima Y, Ikegawa M, Imoto S, Katagiri T, Nakamura Y, Toguchida J. Identification of AFAP1L1 as a prognostic marker for spindle cell sarcomas. Oncogene. 2011; 30: 4015-25. [PubMed]
  3. ○Park J, Katagiri T, Chung S, Kijima K, Nakamura Y. Polypeptide N-acetylgalactosaminyltransferase 6 (GALNT6) disrupts mammary acinar morphogenesis through O-glycosylation of fibronectin. Neoplasia. 2011;13:320-6. [PubMed]

2010

  1. ○Park JH, Nishidate T, Kijima K, Ohashi T, Takegawa K, Fujikane T, Hirata K, Nakamura Y, Katagiri T. Critical roles of MUC1 glycosylation by transactivated GALNT6 (UDP-N-acetyl-D- galactosamine: polypeptide N-acetylgalactosaminyl transferase-6) in mammary carcinogenesis. Cancer Res. 2010;70:2759-69.
  2. ○Park JH, Nishidate T, Nakamura Y, Katagiri T. Critical roles of T-LAK cell-originated protein kinase in cytokinesis. Cancer Sci. 2010;101:403-11.

2009

  1. ○Ueki T, Park JH, Nishidate T, Kijima K, Hirata H, Nakamura Y, Katagiri T. Ubiquitination and downregulation of BRCA1 by UBE2T overexpression in human breast cancer cells. Cancer Res. 2009;69:8752-60.
  2. Ajiro M, Katagiri T, Ueda K, Nakagawa H, Fukukawa C, Lin ML, Park JH, Nishidate T, Daigo Y, Nakamura Y. Involvement of RQCD1 overexpression, a novel cancer-testis antigen, in the Akt pathway in breast cancer cells. Int J Oncol. 2009; 35:673-81.
  3. ○Kim JW, Akiyama M, Park JH, Lin ML, Shimo A, Ueki T, Daigo Y, Tatsuhiko T, Nishidate T, Nakamura Y, Katagiri T. Activation of an estrogen/ estrogen receptor signaling by BIG3 through its inhibitory effect on nuclear transport of PHB2/REA in breast cancer. Cancer Sci. 2009;100:1468-78.
  4. ○Lin ML, Fukukawa C, Park JH, Naito K, Kijima K, Shimo A, Ajiro M, Nishidate T, Nakamura Y, Katagiri T. Involvement of overexpression of G-patch domain containing 2 in breast carcinogenesis. Cancer Sci. 2009;100:1443-50.
  5. Morioka K, Tanikawa C, Ochi K, Daigo Y, Katagiri T, Kawano H, Kawaguchi H, Myoui A, Yoshikawa H, Naka N, Araki N, Kudawara I, Ieguchi M, Nakamura K, Nakamura Y, Matsuda K. Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci. 2009;100:1227-33.
  6. Hanaoka H, Katagiri T, Fukukawa C, Yoshioka H, Yamamoto S, Iida Y, Higuchi T, Oriuchi N, Paudyal B, Paudyal P, Nakamura Y, Endo K. Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10. Annuals of Nuclear Medicine, 2009;23:479-85.
  7. Ueda K, Fukase Y, Katagiri T, Ishikawa N, Irie S, Sato T, Ito H, Nakayama H, Miyagi Y, Tsuchiya E, Kohno N, Shiwa M, Nakamura Y, Daigo Y. Targeted serum glycoproteomics for the discovery of lung cancer-associated glycosylation disorders using lectin-coupled ProteinChip arrays. Proteomics 2009; 9:2182-92.
  8. ○Dobashi S, Katagiri T, Hirota E, Ashida S, Daigo Y, Shuin T, Fujioka T, Miki T, Nakamura Y. Involvement of TMEM22 overexpression in the growth of renal cell carcinoma cells. Oncol Rep. 2009;21:305-12.
  9. ○Fukukawa C, Nagayama S, Tsunoda T, Toguchida J, Nakamura Y, Katagiri T. Activation of non-canonical Dvl-Rac1-JNK pathway by Frizzled-homologue 10 (FZD10) in human synovial sarcoma. Oncogene. 2009; 28:1110-20.
  10. Nagayama S, Yamada E, Kohno Y Aoyama T., Fukukawa C, Kubo H, Watanabe G, Katagiri T, Nakamura, Y, Sakai Y, Toguchida J. Inverse correlation of the upregulation of FZD10 expression and the activation of beta-catenin in synchronous colorectal tumors. Cancer Sci. 2009;99: 2315-26.

2008

  1. Inoue H, Iga M, Nabeta H, Yokoo T, Suehiro Y, Okano S, Inoue M, Kinoh H, Katagiri T, Takayama K, Yonemitsu Y, Hasegawa M, Nakamura Y, Nakanishi Y, Tani K. Non-transmissible SeV encoding GM-CSF is a novel and potent vector system to produce autologous tumor vaccines. Cancer Sci. 2008;99:2315-26.
  2. Konda R, Sugimura J, Sohma F, Katagiri T, Nakamura Y, Fujioka T. Over Expression of Hypoxia-Inducible Protein 2, Hypoxia-Inducible Factor-1 alpha and Nuclear Factor kappaB is putatively involved in acquired renal cyst formation and subsequent tumor transformation in patients with end stage renal failure. J Urol. 2008;180:481-5.
  3. ○Ueki T, Nihidate T, Park JH, Lin ML, Shimo A, Hirata K, Nakamura Y, Katagiri T. Involvement of elevated expression of multiple cell-cycle regulator, DTL/RAMP (denticleless /RA-regulated nuclear matrix associated protein), in the growth of breast cancer cells. Oncogene. 2008, in press.
  4. ○Fukukawa C, Hanaoka H, Nagayama S, Toguchida J, Endo K, Nakamura Y, Katagiri T. Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. Cancer Sci. 2008; 99:432-40
  5. Kamatani Y, Matsuda K, Ohishi T, Ohtsubo S, Yamazaki K, Iida A, Hosono N, Kubo M, Yumura W, Nitta K, Katagiri T, Kawaguchi Y, Kamatani N, Nakamura Y. Identification of a significant association of a single nucleotide polymorphism in TNXB with systemic lupus erythematosus in a Japanese population. J Hum Genet. 2008;53:64-73.
  6. ○Shimo A, Tanikawa C, Lin ML, Nishidate T, Matsuda K, Ueki T, Park JH, Ohta T, Hirata K, Fukuda M, Nakamura Y, Katagiri T. Involvement of KIF2C/MCAK overexpression in mammary carcinogenesis. Cancer Sci. 2008;99:62-70.
  7. Kidokoro T, Tanikawa C, Furukawa Y, Katagiri T, Furukawa Y, Nakamura Y, Matsuda K. CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene. 2008;27:1562-71.